Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France.
PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France.
Molecules. 2020 Mar 14;25(6):1329. doi: 10.3390/molecules25061329.
We report herein the design, synthesis and biological evaluation of new antioxidant and neuroprotective multitarget directed ligands (MTDLs) able to block Ca channels. New dialkyl 2,6-dimethyl-4-(4-(prop-2-yn-1-yloxy)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate MTDLs -, resulting from the juxtaposition of nimodipine, a Ca channel antagonist, and rasagiline, a known MAO inhibitor, have been obtained from appropriate and commercially available precursors using a Hantzsch reaction. Pertinent biological analysis has prompted us to identify the MTDL 3,5-dimethyl-2,6-dimethyl-4-[4-(prop-2-yn-1-yloxy)phenyl]-1,4-dihydro- pyridine- 3,5-dicarboxylate (), as an attractive antioxidant (1.75 TE), Ca channel antagonist (46.95% at 10 μM), showing significant neuroprotection (38%) against HO at 10 μM, being considered thus a hit-compound for further investigation in our search for anti-Alzheimer's disease agents.
我们在此报告了新的抗氧化和神经保护多靶点定向配体(MTDL)的设计、合成和生物学评价,这些配体能够阻断 Ca 通道。新的二烷基 2,6-二甲基-4-(4-(丙炔-1-氧基)苯基)-1,4-二氢吡啶-3,5-二甲酸酯 MTDL-,是将钙通道拮抗剂尼莫地平与已知的 MAO 抑制剂雷沙吉兰并置而成,通过适当的和商业可得的前体,使用 Hantzsch 反应得到。相关的生物学分析促使我们鉴定出 MTDL 3,5-二甲基-2,6-二甲基-4-[4-(丙炔-1-氧基)苯基]-1,4-二氢吡啶-3,5-二甲酸酯()作为一种有吸引力的抗氧化剂(1.75 TE)、Ca 通道拮抗剂(在 10 μM 时为 46.95%),对 HO 具有显著的神经保护作用(在 10 μM 时为 38%),因此被认为是我们寻找抗阿尔茨海默病药物的进一步研究的命中化合物。